Amazon (AMZN) shares retreat after wide Q2 earnings miss >>> READ MORE

5 Mighty Small-Cap Stocks to Buy for 2014

Small cap stocks outperform large in rising rate environments

      View All  


Back in June, molecular diagnostics company Cepheid (CPHD) gained FDA approval for its updated Xpert MRSA/SA BC test (part of its popular GeneXpert system). The test detects infections in blood specific to causes of sepsis in hospitalized patients. The $2.7 billion company reported third-quarter 2013 revenues of $100.1 million, a 24% increase over the same quarter a year ago. Cepheid offers the most popular molecular diagnostic platform on the market; its stock has performed admirably, up 25% over the past six months.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC